Evidence map›Paper›PMID 39248310›Full record

ArticleChemMedChem2024

Phenotypic-Based Discovery and Exploration of a Resorufin Scaffold with Activity against Mycobacterium tuberculosis.

Eric Tran, Chen-Yi Cheung, Lucy Li, Glen P Carter, Robert W Gable, Nicholas P West, Amandeep Kaur, Yi Sing Gee, Gregory M Cook, Jonathan B Baell and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Eric TranMedicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, 3052, Australia.ORCID 0000-0002-6429-5923
Chen-Yi CheungDepartment of Microbiology and Immunology, Otago School of Medical Sciences, University of Otago, Dunedin, 9054, New Zealand.ORCID 0000-0002-5850-0919
Lucy LiDepartment of Microbiology & Immunology, The University of Melbourne at The Peter Doherty Institute for Infection & Immunity, Melbourne, Victoria, 3000, Australia.
Glen P CarterDepartment of Microbiology & Immunology, The University of Melbourne at The Peter Doherty Institute for Infection & Immunity, Melbourne, Victoria, 3000, Australia.ORCID 0000-0002-7306-9362
Robert W GableSchool of Chemistry, University of Melbourne, Parkville, Victoria, 3010, Australia.ORCID 0000-0002-4626-0217
Nicholas P WestSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Queensland, 4072, Australia.ORCID 0000-0003-0955-9890
Amandeep KaurMedicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, 3052, Australia.ORCID 0000-0002-0898-875X
Yi Sing GeeMedicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, 3052, Australia.ORCID 0000-0002-2707-6270
Gregory M CookDepartment of Microbiology and Immunology, Otago School of Medical Sciences, University of Otago, Dunedin, 9054, New Zealand.ORCID 0000-0001-8349-1500
Jonathan B BaellMedicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, 3052, Australia.ORCID 0000-0003-2114-8242
Manuela JörgMedicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, 3052, Australia.ORCID 0000-0002-3116-373X

Funding

Newcastle/Monash University Academic TrackResearch England 131911
6 · The paper itself

Abstract

Tuberculosis remains a leading cause of death by infectious disease. The long treatment regimen and the spread of drug-resistant strains of the causative agent Mycobacterium tuberculosis (Mtb) necessitates the development of new treatment options. In a phenotypic screen, nitrofuran-resorufin conjugate 1 was identified as a potent sub-micromolar inhibitor of whole cell Mtb. Complete loss of activity was observed for this compound in Mtb mutants affected in enzyme cofactor F

Indexed as

Antitubercular AgentsDrug DiscoveryMicrobial Sensitivity TestsMycobacterium tuberculosisOxazinesDose-Response Relationship, DrugHumansMolecular StructureNitrofuransPhenotypeStructure-Activity RelationshipAntitubercular AgentsNitrofuransOxazinesresorufindrug discoveryinfectious diseaseresorufinstructure-activity relationshipstuberculosis

Identifiers

PMID39248310
PMCPMC11648835

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.